SI1235799T1 - Polymorphic form of atorvastatin calcium - Google Patents
Polymorphic form of atorvastatin calciumInfo
- Publication number
- SI1235799T1 SI1235799T1 SI200030648T SI200030648T SI1235799T1 SI 1235799 T1 SI1235799 T1 SI 1235799T1 SI 200030648 T SI200030648 T SI 200030648T SI 200030648 T SI200030648 T SI 200030648T SI 1235799 T1 SI1235799 T1 SI 1235799T1
- Authority
- SI
- Slovenia
- Prior art keywords
- atorvastatin calcium
- polymorphic form
- pharmaceutical compositions
- dosage forms
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16615399P | 1999-11-17 | 1999-11-17 | |
PCT/US2000/031555 WO2001036384A1 (en) | 1999-11-17 | 2000-11-16 | Polymorphic form of atorvastatin calcium |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1235799T1 true SI1235799T1 (en) | 2005-06-30 |
Family
ID=22602039
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200031061T SI1535613T1 (sl) | 1999-11-17 | 2000-11-16 | Postopek za pripravo polimorfne oblike atorvastatin kalcija |
SI200030648T SI1235799T1 (en) | 1999-11-17 | 2000-11-16 | Polymorphic form of atorvastatin calcium |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200031061T SI1535613T1 (sl) | 1999-11-17 | 2000-11-16 | Postopek za pripravo polimorfne oblike atorvastatin kalcija |
Country Status (20)
Country | Link |
---|---|
EP (3) | EP2206497A1 (xx) |
JP (2) | JP2003514798A (xx) |
KR (1) | KR20020063190A (xx) |
CN (1) | CN1423634A (xx) |
AT (2) | ATE288893T1 (xx) |
AU (1) | AU783002B2 (xx) |
CA (1) | CA2392096C (xx) |
CZ (1) | CZ20021642A3 (xx) |
DE (2) | DE60018100T2 (xx) |
ES (2) | ES2234699T3 (xx) |
HR (1) | HRP20020429B8 (xx) |
HU (1) | HUP0203257A3 (xx) |
IL (2) | IL149681A0 (xx) |
PL (1) | PL355805A1 (xx) |
PT (2) | PT1535613E (xx) |
SI (2) | SI1535613T1 (xx) |
SK (1) | SK286789B6 (xx) |
WO (1) | WO2001036384A1 (xx) |
YU (1) | YU35802A (xx) |
ZA (1) | ZA200203755B (xx) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
CA2426632C (en) * | 2000-11-03 | 2008-08-05 | Teva Pharmaceutical Industries, Ltd. | Atorvastatin hemi-calcium form vii |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
CA2626317A1 (en) * | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
RS100003A (xx) * | 2001-06-29 | 2007-02-05 | Warner-Lambert Company, | Kristalni oblici kalcijumove soli /r- (r*,r*)/-2-(4- fluorfenil) beta,delta, dihidroksi-5-(1-metiletil)-3-fenil- -4- fenilamino)karbonil/1h-pirol- heptanske kiseline (2:1)(atorvastatin) |
KR20040019043A (ko) | 2001-07-30 | 2004-03-04 | 닥터 레디스 레보러터리즈 리미티드 | 아토바스탄틴 칼슘의 결정형 ⅵ 및 ⅶ |
US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
EP1480950A4 (en) * | 2002-02-15 | 2005-05-18 | Teva Pharma | NOVEL HEMI-CALCIUM CRYSTALLINE FORMS OF ATORVASTATIN AND METHODS FOR THEIR PREPARATION, AS WELL AS NEW METHODS FOR THE PREPARATION OF FORORVASTATIN HEMI-CALCIUM FORMS I, VIII AND IX |
US7122681B2 (en) | 2002-02-19 | 2006-10-17 | Teva Pharmaceutical Industries, Ltd. | Desolvation process for the production of atorvastatin hemi-calcium essentially free of bound organic solvent |
DE60323835D1 (de) * | 2002-06-13 | 2008-11-13 | Novartis Ag | Calciumsalze von statinen aus indol |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
EP1424324A1 (en) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Crystalline form F of Atorvastatin hemi-calcium salt |
EP1572643A2 (en) * | 2002-11-28 | 2005-09-14 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
CA2465693A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
JP2007536373A (ja) | 2004-05-05 | 2007-12-13 | ファイザー・プロダクツ・インク | アトルバスタチンの塩形態 |
MX2007000765A (es) | 2004-07-20 | 2007-03-28 | Warner Lambert Co | Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1). |
MX2007003652A (es) | 2004-09-28 | 2009-02-16 | Teva Pharma | Proceso para preparar formas de calcio de atorvastatina sustancialmente libre de impurezas. |
US20060106230A1 (en) | 2004-10-18 | 2006-05-18 | Michael Pinchasov | Processes for preparing amorphous atorvastatin hemi-calcium |
JP2008517992A (ja) | 2004-10-28 | 2008-05-29 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アモルファスのアトルバスタチンを形成する方法 |
WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
US20090208539A1 (en) | 2004-11-22 | 2009-08-20 | Adel Penhasi | Stable atorvastatin formulations |
CA2499047A1 (en) | 2005-03-01 | 2006-09-01 | Apotex Pharmachem Inc. | Process for producing atorvastatin hemicalcium |
CN101268047B (zh) * | 2005-08-15 | 2012-11-07 | 箭锋国际有限公司 | 结晶和无定形阿托伐他汀钠 |
BRPI0614279A2 (pt) | 2005-08-15 | 2012-11-06 | Arrow Int Ltd | atorvastatina sódica cristalina e amorfa |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
PT1957452E (pt) | 2005-11-21 | 2010-05-25 | Warner Lambert Co | Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico |
EP1923057A1 (en) | 2005-11-21 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Atorvastatin pharmaceutical formulation |
EP1808162A1 (en) | 2005-11-21 | 2007-07-18 | Teva Pharmaceutical Industries Ltd. | Atorvastatin pharmaceutical formulation |
BRPI0610344A2 (pt) * | 2005-12-13 | 2016-11-29 | Teva Pharma | forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal |
EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
US20090240064A1 (en) * | 2006-02-22 | 2009-09-24 | Venkata Panakala Rao Gogulapati | Crystalline form of atorvastatin hemi-calcium |
EP2132171A4 (en) * | 2007-03-02 | 2010-11-17 | Dong A Pharm Co Ltd | NOVEL CRYSTALLINE FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES |
US8664390B2 (en) | 2007-06-29 | 2014-03-04 | Generics (Uk) Limited | Process for the introduction of hydroxyethoxy side chain in bosentan |
EP2185527A2 (en) * | 2007-07-11 | 2010-05-19 | Actavis Group PTC EHF | Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium |
JP2011500780A (ja) | 2007-10-24 | 2011-01-06 | ジェネリクス・(ユーケー)・リミテッド | 新規結晶形 |
PT2245018T (pt) | 2008-02-08 | 2017-12-05 | Generics Uk Ltd | Processo para preparar bosentano |
EP2350028A1 (en) | 2008-11-03 | 2011-08-03 | Generics [UK] Limited | Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers |
EP2327682A1 (en) * | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
SI2373609T1 (sl) * | 2008-12-19 | 2013-12-31 | Krka, D.D., Novo Mesto | Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov |
CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
CN102249978A (zh) * | 2011-06-09 | 2011-11-23 | 浙江金立源药业有限公司 | 阿托伐他汀钙的ky晶型及制备方法 |
CN103483238B (zh) * | 2013-08-20 | 2014-12-31 | 蚌埠丰原医药科技发展有限公司 | 阿托伐他汀钙三水合物的制备方法 |
MA39033A1 (fr) | 2013-11-15 | 2017-11-30 | Akebia Therapeutics Inc | Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations |
CN104945300B (zh) * | 2015-06-17 | 2017-05-10 | 北京嘉林药业股份有限公司 | 一种ⅰ型阿托伐他汀钙的纯化方法 |
CN105085362B (zh) * | 2015-09-18 | 2018-01-05 | 浙江海森药业有限公司 | 高纯度结晶型阿托伐他汀钙的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
CA2150372C (en) * | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
EE03606B1 (et) * | 1995-07-17 | 2002-02-15 | Warner-Lambert Company | Kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hept aanhappehemikaltsiumsool (atorvastatiin) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
-
2000
- 2000-11-16 EP EP10157435A patent/EP2206497A1/en not_active Withdrawn
- 2000-11-16 CN CN00818409A patent/CN1423634A/zh active Pending
- 2000-11-16 SI SI200031061T patent/SI1535613T1/sl unknown
- 2000-11-16 PT PT04027375T patent/PT1535613E/pt unknown
- 2000-11-16 PT PT00978744T patent/PT1235799E/pt unknown
- 2000-11-16 ES ES00978744T patent/ES2234699T3/es not_active Expired - Lifetime
- 2000-11-16 CA CA002392096A patent/CA2392096C/en not_active Expired - Fee Related
- 2000-11-16 YU YU35802A patent/YU35802A/sh unknown
- 2000-11-16 AT AT00978744T patent/ATE288893T1/de not_active IP Right Cessation
- 2000-11-16 AT AT04027375T patent/ATE478665T1/de not_active IP Right Cessation
- 2000-11-16 JP JP2001538875A patent/JP2003514798A/ja not_active Withdrawn
- 2000-11-16 WO PCT/US2000/031555 patent/WO2001036384A1/en active IP Right Grant
- 2000-11-16 AU AU16173/01A patent/AU783002B2/en not_active Ceased
- 2000-11-16 DE DE60018100T patent/DE60018100T2/de not_active Expired - Lifetime
- 2000-11-16 KR KR1020027006304A patent/KR20020063190A/ko not_active Application Discontinuation
- 2000-11-16 DE DE60044884T patent/DE60044884D1/de not_active Expired - Lifetime
- 2000-11-16 SK SK674-2002A patent/SK286789B6/sk not_active IP Right Cessation
- 2000-11-16 ES ES04027375T patent/ES2349364T3/es not_active Expired - Lifetime
- 2000-11-16 CZ CZ20021642A patent/CZ20021642A3/cs unknown
- 2000-11-16 IL IL14968100A patent/IL149681A0/xx active IP Right Grant
- 2000-11-16 HU HU0203257A patent/HUP0203257A3/hu unknown
- 2000-11-16 EP EP04027375A patent/EP1535613B1/en not_active Expired - Lifetime
- 2000-11-16 PL PL00355805A patent/PL355805A1/xx not_active Application Discontinuation
- 2000-11-16 SI SI200030648T patent/SI1235799T1/xx unknown
- 2000-11-16 EP EP00978744A patent/EP1235799B1/en not_active Expired - Lifetime
-
2002
- 2002-05-10 ZA ZA200203755A patent/ZA200203755B/en unknown
- 2002-05-15 IL IL149681A patent/IL149681A/en unknown
- 2002-05-16 HR HR20020429A patent/HRP20020429B8/xx not_active IP Right Cessation
-
2009
- 2009-02-12 JP JP2009030514A patent/JP2009102439A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20020429A2 (en) | Polymorphic form of atorvastatin calcium | |
IL150223A (en) | Lipopeptides and pharmaceuticals containing them | |
IL156280A0 (en) | Crystalline forms of atorvastatin | |
HUP0001219A3 (en) | Pharmaceutical compositions containing compounds of neurotrophic effect | |
ATE277615T1 (de) | Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin | |
HK1025904A1 (en) | Pharmaceutical composition for combination of piperidinoalkanol-decongestant | |
IL147970A0 (en) | Pharmaceutical compositions containing tripeptides | |
IL141157A0 (en) | Salt form of pantoprazole and pharmaceutical compositions containing the same | |
HUP0203311A3 (en) | New pharmaceutical compositions of prolonged effect | |
EE05182B1 (et) | Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon | |
EP1404303A4 (en) | STABLE PHARMACEUTICAL COMPOSITIONS BASED ON PRAVASTATIN | |
ZA966953B (en) | Pharmaceutical composition. | |
HUP0203558A3 (en) | Substituted pyrroles as antiproliferative compounds for the treatment of cancer and pharmaceutical compositions containing them | |
IL120005A0 (en) | Pharmaceutical compositions for the treatment of the eye | |
HUP0302531A3 (en) | Pharmaceutical compositions containing citalopram | |
EP1057829A4 (en) | Condensed pyrimidine derivatives and pharmaceutical compositions containing them | |
KR100248098B1 (en) | Pharmaceutical composition for the treatment of dementia | |
HUP0400007A2 (hu) | Alkanoil-L-karnitin alkalmazása anhedónia kezelésére szolgáló gyógyászati készítmény előállítására | |
HUP0400531A3 (en) | Hydantoin compounds useful as anti-inflammatory agents and pharmaceutical compositions containing them | |
IL122883A0 (en) | Pharmaceutical compositions for the treatment of dyskinesias | |
IL127102A0 (en) | Pharmaceutical compositions for the treatment of dyskinesias | |
IL137190A0 (en) | Pharmaceutical compositions for the treatment of dyskinesias | |
SI1083887T1 (sl) | Farmacevtski sestavki za zdravljenje ulkusov |